Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patients with relapsed, or...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Hematol
Egile Nagusiak: Baljevic, Muhamed, Zaman, Shadia, Baladandayuthapani, Veerabhadran, Lin, Yan Heather, de Partovi, Claudia Morales, Berkova, Zuzana, Amini, Behrang, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Fu, Min, Cleeland, Charles S., Wang, Xin Shelley, Stellrecht, Christine M., Davis, Richard E., Gandhi, Varsha, Orlowski, Robert Z.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2017
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://ncbi.nlm.nih.gov/pubmed/28337527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2980-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak